Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Losmapimod (GSK-AHAB) 是一种可口服的特异性 p38 MAPK 抑制剂,抑制 p38α 和 p38β 的 pKi 值分别为 8.1 和 7.6。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 247 | 现货 | ||
5 mg | ¥ 385 | 现货 | ||
10 mg | ¥ 622 | 现货 | ||
25 mg | ¥ 1,270 | 现货 | ||
50 mg | ¥ 2,120 | 现货 | ||
100 mg | ¥ 3,670 | 现货 | ||
500 mg | ¥ 7,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 451 | 现货 |
产品描述 | Losmapimod (GSK-AHAB) (GW856553X; SB856553; GSK-AHAB) is a specific, potent, and orally active p38 MAPK inhibitor (pKi: 8.1/7.6 for p38α/β). |
靶点活性 | p38β:7.6(pKi), p38α:8.1(pKi) |
激酶实验 | DNA binding assays: All reactions are performed in black non-binding polystyrene 384-well plates with reaction volumes of 30–100 μL. Purified DNA strand exchange proteins and chemical compounds are pre-incubated at room temperature for 5 minutes; they are then further incubated at 37°C for 30 min with 100 nM of ssDNA substrate, consisting of a 45-mer poly-dT tagged with Alexa 488 at the 5' terminus (synthesized and purified by Integrated DNA Technologies). Reactions are performed in 20 mM HEPES pH 7.5, 10 mM MgCl2, 0.25 μM BSA, 2% glycerol, 30 mM NaCl, 4% DMSO and 2 mM ATP. Some conditions included DTT or TCEP (tris(2-carboxyethyl)phosphine) as indicated. DNA binding is measured as a function of fluorescence polarization (FP) with a Safire2 plate reader, using the following settings: excitation 470±5 nM, emission 530±5 nM, 10 reads/well, Z height and G factor auto-calibrated from control wells. Displayed error bars represent standard deviation. For experiments involving a titration of protein concentrations, data are fit to an equation that accounts for the cooperative nature by which recombinase proteins bind DNA. For experiments involving a titration of RI-1, protein concentrations are selected to give an ~80% saturation of the FP signal in the absence of RI-1. |
别名 | GSK-AHAB, GW856553X, 6-[5-(环丙基氨基甲酰基)-3-氟-2-甲基苯基]-N-(2,2-二甲基丙基)吡啶-3-甲酰胺, GW856553, 洛批莫德, SB856553 |
分子量 | 383.46 |
分子式 | C22H26FN3O2 |
CAS No. | 585543-15-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 39 mg/mL (101.7 mM)
DMSO: 71 mg/mL (185.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.6078 mL | 13.0392 mL | 26.0783 mL | 65.1958 mL |
5 mM | 0.5216 mL | 2.6078 mL | 5.2157 mL | 13.0392 mL | |
10 mM | 0.2608 mL | 1.3039 mL | 2.6078 mL | 6.5196 mL | |
20 mM | 0.1304 mL | 0.652 mL | 1.3039 mL | 3.2598 mL | |
50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.3039 mL | |
100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.652 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Losmapimod 585543-15-3 Autophagy MAPK p38 MAPK GSK-AHAB GW856553X 6-[5-(环丙基氨基甲酰基)-3-氟-2-甲基苯基]-N-(2,2-二甲基丙基)吡啶-3-甲酰胺 GW 856553 inhibit GW856553 SB-856553 GW-856553 洛批莫德 SB856553 SB 856553 Inhibitor inhibitor